2025
SJR Q2
JCR Q3 · 1,7
123 matched articles
SCIE
Journal detail
Clinical Hemorheology and Microcirculation
- Publisher
- SAGE Publications Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
1386029118758622
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,66
- Quartile Q2
- H-Index 65
- Cites/doc 1,6
- Docs (3y) 362
- Cites (3y) 596
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,7
- 5Y JIF 1,6
- JCI 0,69
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cardiology and Cardiovascular Medicine Q2
- Hematology Q2
- Physiology Q3
- Physiology (medical) Q3
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Hematology | Peripheral Vascular Diseases
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,66 | 1,7 | 1,6 | 0,69 | Q2 | 65 |
| 2024 | Q2 | — | 0,604 | — | — | 0,72 | Q2 | 64 |
| 2023 | Q3 | Q3 | 0,456 | 2,1 | 1,8 | 0,56 | Q2 | 64 |
| 2022 | Q3 | Q3 | 0,509 | 2,1 | 1,9 | 0,5 | Q3 | 64 |
| 2021 | Q3 | Q3 | 0,512 | 2,4 | 2 | 0,5 | Q3 | 64 |
| 2020 | Q3 | Q3 | 0,546 | 2,4 | 1,8 | 0,49 | Q3 | 64 |
| 2019 | Q2 | Q4 | 0,523 | 1,7 | 1,3 | 0,43 | Q3 | 64 |
| 2018 | — | Q4 | — | 1,6 | 1,5 | 0,42 | Q3 | — |
| 2017 | Q2 | Q3 | 0,512 | 1,9 | 1,6 | 0,41 | Q3 | 64 |
| 2016 | Q2 | Q3 | 0,534 | 1,7 | 1,6 | — | — | 64 |
| 2015 | Q2 | Q3 | 0,723 | 1,8 | 1,9 | — | — | 64 |
| 2014 | Q2 | Q3 | 0,81 | 2,2 | 2,1 | — | — | 64 |
| 2013 | Q2 | Q3 | 0,591 | 2,2 | 2 | — | — | 64 |
| 2012 | Q2 | — | 0,516 | — | — | — | — | 64 |
| 2011 | Q2 | Q1 | 0,555 | 3,4 | 2,1 | — | — | 64 |
| 2010 | Q2 | Q2 | 0,579 | 2,8 | 1,9 | — | — | 64 |
| 2009 | — | Q3 | — | 1,8 | 1,5 | — | — | — |
| 2008 | — | Q3 | — | 1,8 | 1,4 | — | — | — |
| 2007 | — | Q4 | — | 1 | 1 | — | — | — |
| 2006 | — | Q3 | — | 1,2 | — | — | — | — |
| 2005 | — | Q4 | — | 1 | — | — | — | — |
| 2004 | — | Q4 | — | 0,6 | — | — | — | — |
| 2003 | — | Q4 | — | 0,8 | — | — | — | — |
| 2002 | — | Q4 | — | 0,6 | — | — | — | — |
| 2001 | — | Q4 | — | 0,3 | — | — | — | — |
| 2000 | — | Q4 | — | 0,6 | — | — | — | — |
| 1999 | — | Q4 | — | 0,4 | — | — | — | — |
| 1998 | — | Q3 | — | 0,7 | — | — | — | — |
| 1997 | — | Q4 | — | 0,3 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | HEMATOLOGY | SCIE | Q3 | Q2 | 73/103 |
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 72/100 |
| 2024 | HEMATOLOGY | SCIE | — | Q2 | — |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | — | Q2 | — |
| 2023 | HEMATOLOGY | SCIE | Q3 | Q2 | 58/97 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 51/96 |
| 2022 | HEMATOLOGY | SCIE | Q4 | Q3 | 63/79 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 50/68 |
| 2021 | HEMATOLOGY | SCIE | Q4 | Q3 | 62/78 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 50/67 |
| 2020 | HEMATOLOGY | SCIE | Q4 | Q3 | 58/76 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 47/65 |
| 2019 | HEMATOLOGY | SCIE | Q4 | Q3 | 58/76 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 52/65 |
| 2018 | HEMATOLOGY | SCIE | Q4 | Q3 | 57/73 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 50/65 |
| 2017 | HEMATOLOGY | SCIE | Q3 | Q3 | 51/71 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 45/65 |
| 2016 | HEMATOLOGY | SCIE | Q3 | — | 52/70 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 48/63 |
| 2015 | HEMATOLOGY | SCIE | Q3 | — | 52/70 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 45/63 |
| 2014 | HEMATOLOGY | SCIE | Q3 | — | 42/68 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 39/60 |
| 2013 | HEMATOLOGY | SCIE | Q3 | — | 42/68 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 38/65 |
| 2011 | HEMATOLOGY | SCIE | Q2 | — | 25/68 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 15/68 |
| 2010 | HEMATOLOGY | SCIE | Q2 | — | 30/66 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 23/68 |
| 2009 | HEMATOLOGY | SCIE | Q3 | — | 44/61 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 35/61 |
| 2008 | HEMATOLOGY | SCIE | Q3 | — | 45/62 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 35/56 |
| 2007 | HEMATOLOGY | SCIE | Q4 | — | 57/63 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 44/54 |
| 2006 | HEMATOLOGY | SCIE | Q4 | — | 49/61 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 34/52 |
| 2005 | HEMATOLOGY | SCIE | Q4 | — | 53/60 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 40/51 |
| 2004 | HEMATOLOGY | SCIE | Q4 | — | 53/62 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 47/51 |
| 2003 | HEMATOLOGY | SCIE | Q4 | — | 51/62 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 42/52 |
| 2002 | HEMATOLOGY | SCIE | Q4 | — | 55/61 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 45/52 |
| 2001 | HEMATOLOGY | SCIE | Q4 | — | 56/59 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 47/50 |
| 2000 | HEMATOLOGY | SCIE | Q4 | — | 55/60 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 39/45 |
| 1999 | HEMATOLOGY | SCIE | Q4 | — | 53/60 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 39/44 |
| 1998 | HEMATOLOGY | SCIE | Q4 | — | 47/59 |
| 1998 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 26/39 |
| 1997 | HEMATOLOGY | SCIE | Q4 | — | 55/59 |
| 1997 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 35/38 |